5'PPP-RNA

mediates activation of RIG-I can suppress replication of influenza viruses irrespective of their genetic make-up, pathogenicity, and drug-sensitivity status

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cui, Jianzhou: 1 article (01/2020)
2.	Fairhurst, Anna-Marie: 1 article (01/2020)
3.	Foo, Sok Lin: 1 article (01/2020)
4.	Lim, Lina H K: 1 article (01/2020)
5.	Sachaphibulkij, Karishma: 1 article (01/2020)
6.	Yap, Gracemary L R: 1 article (01/2020)
7.	Fujita, Takashi: 1 article (07/2010)
8.	Jogi, Michihiko: 1 article (07/2010)
9.	Julkunen, Ilkka: 1 article (07/2010)
10.	Morimoto, Shiho: 1 article (07/2010)

Related Diseases

1.	Virus Diseases (Viral Diseases) 07/22/2010 - "In doing so we discovered that viral infection as well as transfection with 5'ppp-RNA resulted in the redistribution of IPS-1 to form speckle-like aggregates in cells. " 07/22/2010 - "Virus-infection or 5'ppp-RNA activates antiviral signal through redistribution of IPS-1 mediated by MFN1."
2.	Neoplasms (Cancer) 09/01/2023 - "Because these tumors harbor a severely impaired cGAS-STING axis, but they still retain a largely functional RIG-I pathway, another critical mediator of adaptive and innate immune responses, we asked whether RIG-I activation by the 5'ppp-RNA RIG-I agonist M8 would represent a therapeutically viable option to treat HPV+ cancers. "
3.	Infections 01/01/2020 - "RIG-I activation by 5'ppp-RNA stimulates the production of IFNβ from lung epithelial cells to the same extent as monocytic cells, albeit very late after infection at 48-72 h, through IRF3 and STAT1 activation. "
4.	Bites and Stings (Sting) 09/01/2023 - "Because these tumors harbor a severely impaired cGAS-STING axis, but they still retain a largely functional RIG-I pathway, another critical mediator of adaptive and innate immune responses, we asked whether RIG-I activation by the 5'ppp-RNA RIG-I agonist M8 would represent a therapeutically viable option to treat HPV+ cancers. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)